Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2019

Open Access 01-12-2019 | Dyspareunia | Research article

Effect of a multi-ingredient based food supplement on sexual function in women with low sexual desire

Authors: S. Palacios, E. Soler, M. Ramírez, M. Lilue, D. Khorsandi, F. Losa

Published in: BMC Women's Health | Issue 1/2019

Login to get access

Abstract

Background

Studies have demonstrated that women with low desire and low excitement have negative feelings regarding their physical and emotional satisfaction, as well as their happiness. In this study, we evaluate the efficacy of Libicare® - a multi-ingredient food supplement - to improve sexual function in postmenopausal women.

Methods

This was an exploratory, prospective, non-controlled, observational study. Postmenopausal women aged 45–65 with a risk of sexual dysfunction (Female Sexual Function Index (FSFI) < 25.83) were included during routine clinical visits and treated with 2 tablets of Libicare® daily for 2 months. Libicare® is an oral food supplement containing Trigonella foenum graecum, Turnera diffusa, Tribulus terrestris, and Ginkgo biloba dry extracts. Primary endpoint: change vs. baseline in FSFI score. Secondary endpoints: 1) changes in testosterone and serum steroid levels of free testosterone and sex hormone-binding globulin (SHBG) levels and 2) tolerability.

Results

A total of 29 patients (mean age: 54.69 years) were included. FSFI mean (SD) score showed a significant increase: 20.15 (4.48) vs 25.03 (6.94), baseline vs final; p = 0.0011, paired t-test. Most patients (86.2%) increased their FSFI score. All FSFI domains, except dyspareunia, showed significant increases. The highest increase was observed in the desire domain (p = 0.0004). Testosterone and SHBG levels were assessed in 21 patients. A significant increase in testosterone level was observed: 0.41 (0.26) vs. 0.50 (0.34) pg/mL, baseline vs. final; p = 0.038, Wilcoxon test. 52.4% of patients increased their testosterone levels. Finally, a significant decrease was observed in SHBG level: 85 (32.9) vs. 73 (26.8) nmol/L, baseline vs. final; p = 0.0001; paired t-test. 95.2% of patients decreased their SHBG levels.

Conclusion

In this pilot study, a significant improvement in sexual function and related hormone levels was observed with Libicare®. Further studies must be conducted to confirm these exciting results.

Trial registration

Current Controlled Trial ISRCTN12928573. Date of registration: 28/March/2019. Retrospectively registered.
Literature
1.
Basson R, Berman J, Burnett A, DeRogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163:888–93.CrossRef
2.
Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med. 2006;3:212–22.CrossRef
3.
Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's international Study of health and sexuality (WISHeS). Menopause. 2006;13:46–56.CrossRef
4.
Moreira ED Jr, Glasser DB, Gingell C. Sexual activity, sexual dysfunction and associated help-seeking behaviours in middle-aged and older adults in Spain: a population survey. World J Urol. 2005;23:422–9.CrossRef
5.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112:970–8.CrossRef
6.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537–44.CrossRef
7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision. Washington, DC: American Psychiatric Press; 2013.CrossRef
8.
Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med. 2004;1:82–6.CrossRef
9.
Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab. 2005;90:4836–45.CrossRef
10.
Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res. 2005;17:148–53.CrossRef
11.
Schiffer L, Arlt W, Storbeck KH. Intracrine androgen biosynthesis, metabolism and action revisited. Mol Cell Endocrinol. 2018;465:4–26.CrossRef
12.
Steels E, Steele ML, Harold M, Coulson S. Efficacy of a proprietary Trigonella foenum-graecum L. of-husked seed extract in reducing menopausal symptoms in otherwise healthy women: a double-blind, randomized, placebo-controlled Study. Phytother Res. 2017;31(9):1316–22.CrossRef
13.
Shamshad Begum S, Jayalakshmi HK, Vidyavathi HG, Gopakumar G, Abin I, Balu M, Geetha K, Suresha SV, Vasundhara M, Krishnakumar IM. A novel extract of fenugreek husk (FenuSMART™) alleviates postmenopausal symptoms and helps to establish the hormonal balance: a randomized, double-blind, placebo-controlled Study. Phytother Res. 2016;30(11):1775–84.CrossRef
14.
Rao A, Steels E, Beccaria G, Inder WJ, Vitetta L. Influence of a specialized Trigonella foenum-graecum seed extract (Libifem), on testosterone, estradiol and sexual function in healthy menstruating women, a randomised placebo controlled Study. Phytother Res. 2015;29(8):1123–30.CrossRef
15.
Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J Sex Marital Ther. 2006;32(5):369–78.CrossRef
16.
Polan ML, Hochberg RB, Trant AS, Wuh HC. Estrogen bioassay of ginseng extract and ArginMax, a nutritional supplement for the enhancement of female sexual function. J Women's Health (Larchmt). 2004;13(4):427–30.CrossRef
17.
Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541–9.CrossRef
18.
de Souza KZ, Vale FB, Geber S. Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. Menopause. 2016;23(11):1252–6.CrossRef
19.
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.CrossRef
20.
Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.CrossRef
21.
Stephenson KR, Toorabally N, Lyons L, M Meston C. Further validation of the female sexual function index: specificity and associations with clinical interview data. J Sex Marital Ther. 2016 Jul 3;42(5):448–61.CrossRef
22.
Meston CM. Validation of the female sexual function index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003 Jan-Feb;29(1):39–46.CrossRef
23.
Revicki DA, Margolis MK, Bush EN, De Rogatis LR, Hanes V. Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2011 Aug;8(8):2237–45.CrossRef
24.
Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002;77(Suppl)4):S42–8.CrossRef
25.
Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294:91–6.CrossRef
26.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017;92(1):114–28.CrossRef
27.
Perelman MA. Female sexual dysfunction and the central nervous system. J Sex Med. 2007;4:257–9.CrossRef
28.
Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK, et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res. 1999;105:105–16.CrossRef
29.
Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9(4):1134–48.CrossRef
30.
Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J, APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005–17.CrossRef
31.
Palacios S. Androgens and female sexual function. Maturitas. 2007;57(1):61–5.CrossRef
32.
Armeni E, Lambrinoudaki I. Androgens and cardiovascular disease in women and men. Maturitas. 2017;104:54–72.CrossRef
33.
Spark RF. Intrinsa fails to impress FDA advisory panel. Int J Impot Res. 2005;17:283–4.CrossRef
34.
Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R, DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793–804.CrossRef
35.
Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40.CrossRef
36.
English C, Muhleisen A, Rey JA. Flibanserin (Addyi): the first FDA-approved treatment for female sexual interest/arousal disorder in premenopausal women. P T. 2017;42(4):237–41.PubMedPubMedCentral
37.
Aftab A, Chen C, McBride J. Flibanserin and its discontents. Arch Womens Ment Health. 2017;20(2):243–7.CrossRef
38.
Akhtari E, Raisi F, Keshavarz M, Hosseini H, Sohrabvand F, Bioos S, Kamalinejad M. Ghobadi Atribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo - controlled study. Daru. 2014;22:40.CrossRef
39.
Zhao J, Dasmahapatra AK, Khan SI, Khan IA. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol. 2008;120(3):387–93.CrossRef
40.
Wu AND, Li S, Cui W, Zu X, Du J, Wang F. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilation. Phytomedicine. 2008;15(3):164–9.CrossRef
Metadata
Title
Effect of a multi-ingredient based food supplement on sexual function in women with low sexual desire
Authors
S. Palacios
E. Soler
M. Ramírez
M. Lilue
D. Khorsandi
F. Losa
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2019
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-019-0755-9

Other articles of this Issue 1/2019

BMC Women's Health 1/2019 Go to the issue

Research article

The myth of menstruation: how menstrual regulation and suppression impact contraceptive choice

Research article

Shifts in FGM/C practice in Sudan: communities’ perspectives and drivers

Research article

Experience obtaining legal abortion in Uruguay: knowledge, attitudes, and stigma among abortion clients

Research article

Factors associated with breast cancer screening awareness and practices of women in Addis Ababa, Ethiopia

Research article

Predictors of contraceptive use among adolescent girls and young women (AGYW) aged 15 to 24 years in South Africa: results from the 2012 national population-based household survey

Research article

“The importance of awareness, support and inner strength to balance everyday life” - a qualitative study about women’s experiences of a workplace health promotion program in human service organizations in Sweden